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To understand patients’ perceptions of clinical trials (CTs) is the principal step in the enrolment of patients to CTs. However, these
perceptions in eastern countries are very rare. From 12 February 2007 to 13 April 2007, we consecutively distributed the
questionnaire to 842 cancer patients who initiated a first cycle of chemotherapy regardless of each treatment step in the Seoul
National University Hospital. Younger age, higher educational degree, higher economic status, and possession of private cancer
insurance were related with significantly higher awareness of CTs (P¼0.001, P¼0.006, P¼0.002, and P¼0.009, respectively).
However, unlike awareness, perceptions on benefits of CTs were not changed according to age, educational degree, and economic
status (P¼0.709, P¼0.920, and P¼0.847, respectively). Willingness was also not changed according to age, educational degree,
economic status, and private cancer insurance (P¼0.381, P¼0.775, P¼0.887, and P¼0.392, respectively). Instead, males and
heavily treated patients had more positive perceptions on benefits (P¼0.002 and P¼0.001, respectively) and more willingness to
participate in CTs (OR¼1.17, 1.14–2.75: OR¼1.59, 1.01–2.51, respectively). In summary, cancer patients’ awareness of CTs,
perceptions on the benefit in CTs, and willingness to participate are differently influenced by diverse medical and social conditions.
This information would be very helpful for investigators to properly conduct CTs in eastern cancer patients.
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Nowadays, the molecular biological characteristics of tumours
have been thoroughly identified. On the basis of these results,
many novel agents and modalities have been developed and are
being studied for clinical use. Cancer clinical trials (CTs) are
needed to establish new treatment options through evaluating the
efficacy and toxicity of novel therapy. In addition, participation in
CTs gives patients a chance to receive the most up-to-date therapy
(Cobau, 1994). Participation in CTs is also frequently related to a
higher survival rate (Stiller, 1994). Therefore, CTs are an important
issue in oncology, and the need for such studies is continuously
growing.
However, in the process of conducting CTs, there are some
limitations, including administrative barriers, low accrual rate,
ethical issues, problem with referral systems, low research funding,
communication barriers, and other issues (Lara et al, 2001; Kaas
et al, 2005; Dilts and Sandler, 2006; Ho et al, 2006). Of these
limitations, low accrual rate is the most important barrier to
conducting CTs. Sufficient numbers of patients to drive appro-
priate outcomes are a necessary component. However, CT
participants represented approximately 1.7% of the total number
of incident cancer cases during the study period from 2000 to 2002
in the United States (Murthy et al, 2004). In the East, accrual rate
might also be low. Low accrual rates may also often prolong the
duration of a CT, delay the analysis of an important outcome, or
lead to early closure of CTs (Haidich and Ioannidis, 2001).
Therefore, it is necessary to identify and overcome the barriers of
the enrolment of patients into CTs.
To increase patient participation in CTs, it is very important
to understand the perceptions of cancer patients regarding CTs.
A few studies regarding accrual barriers of CTs reported that
participation in CTs was influenced by social, economic, and
cultural backgrounds as well as medical decisions (Lara et al, 2001,
2005; Sateren et al, 2002; Paterniti et al, 2005; Tu et al, 2005). Most
studies addressing the perceptions of cancer patients on CTs have
been conducted in western countries (Comis et al, 2003) and study
populations were usually limited to particular cancer types or
participants in phase I research (Weeks et al, 1998; Meropol et al,
2003; Agrawal et al, 2006). Considering the social and cultural
differences between eastern and western countries, it is difficult to
directly extrapolate outcomes obtained in the West to the people of
the East. Moreover, the number of CTs conducted in the East has
recently begun to increase rapidly. However, the prospective data
addressing these issues in eastern populations remain quite
limited.
Thus, we conducted this prospective study to determine how
cancer patients view CTs according to patient conditions and how
these perceptions influence the willingness of cancer patients to
participate in CTs in the East.
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Patients
From 12 February 2007 to 13 April 2007, we prospectively surveyed
cancer patients who initiated the first cycle of their chemotherapy
at Seoul National University Hospital in Korea. For example,
patients who started their adjuvant chemotherapy, first-line
palliative chemotherapy, second-line palliative chemotherapy,
and so on were consecutively enrolled.
With the agreement of each patient, personal information was
gathered. Disease status was retrieved from medical records. These
perceptions from patients were compared with those of physicians.
We received informed consent from all individuals before
enrolment in this study.
Questionnaire
A questionnaire was distributed to cancer patients to be matched
with the study criteria consecutively. For patients to be enrolled in
actual cancer CT, their physicians also received the questionnaire
to assess their perceptions on CTs. The contents of the
questionnaire included: (1) patients’ awareness of cancer CTs
and sources of information for cancer CTs, (2) perceptions of
patients and physicians associated with the benefits of CTs
compared with conventional therapy, and (3) willingness of
patients to participate in CTs and the reason of participation or
non-participation in cancer CT.
Quantitative benefit of participation in cancer CT
A visual analogue scale (VAS) between 0 and 10 was used in a
survey of the perceptions on the effect of each treatment. In the
VAS score, zero points indicate ‘never effective’ and 10 points
indicate ‘effective enough to cure’. The ‘benefits’ of participating in
CTs were calculated with the difference of the VAS score between a
CT and a conventional therapy (benefit¼effect of CT–effect of
conventional therapy).
Statistical analysis
The w
2-test was used in the analysis of awareness and willingness
according to patient characteristics. To show perceptions on the
benefit of a CT, the VAS score with multiple factors was analysed
by t-test or one-way analysis of variance (ANOVA). Odds ratios
obtained by logistic regression revealed the influence of patients’
awareness and the benefit of the CT on the willingness to
participate. Multivariate analysis was also conducted by logistic
regression. To evaluate the difference of perceptions between
patients and physicians regarding the effect of treatment, VAS
scores of both groups were analysed by paired t-test. All analyses
were performed using SPSS for Windows, version 12.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
A total of 842 cancer patients were enrolled who initiated their first
cycle of chemotherapy. Forty-seven CTs were available for
enrolment during this study period in Seoul National University
Hospital. In all, 12.4% of total patients participated in cancer CTs
during study period (105 out of 842). Among 842 patients, 524
patients completed the questionnaire (62.1%). Among 105 patients
who were actually enrolled in cancer CTs, 42.9% responded to the
questionnaire (45 out of 105). In contrast, among patients who
were not enrolled in cancer CTs, the rate of responders to the
questionnaire was higher than in real participants in cancer CTs
(479 out of 737, 65.0%; Po0.001).
Table 1 Baseline characteristics
Variable Frequency (N¼524) %
Sex
Male 239 45.6
Female 285 54.4
Age (years)
p30 12 2.3
30o to p40 59 11.3
40o to p50 121 23.1
50o to p60 128 24.4
60o to p70 161 30.7
70o 43 8.3
Disease status
Neoadjuvant 25 4.8
Adjuvant 169 32.3
Metastatic, first line 160 30.5
Metastatic, second line 79 15.1
Metastatic, third line 49 9.4
Metastatic, fourth line 21 4.0
Metastatic, fifth line 11 2.1
Metastatic, sixth line 8 1.5
Metastatic, seventh line 2 0.4
Educational degree
Postgraduate 37 7.1
University 153 29.2
High school 185 35.3
Middle school 57 10.9
Elementary school 58 11.1
Uneducated 10 1.9
Unknown 24 4.6
Religion
Buddhism 162 30.9
Christian 153 29.2
Catholicism 74 14.1
Others 79 15.1
Unknown 56 10.7
Diagnosis
Breast 168 32.1
Lung 98 18.7
Stomach 47 9.0
Colorectal 70 13.4
Hepatocellular 14 2.7
Biliary 21 4.0
Pancreas 14 2.7
Lymphoma 12 2.3
Head and neck 23 4.4
Sarcoma 11 2.1
Gynecology and genitourinary 11 2.1
Oesophagus 8 1.5
Others
a 27 5.2
Marital status
Single 34 6.5
Married 425 81.1
Bereavement 29 5.5
Divorced 20 3.8
Unknown 16 3.1
Economic status
45
b 64 12.2
5X to 44 46 8.8
4X to 43 78 14.9
3X to 42 58 11.1
2X to 41 93 17.7
1X 129 24.6
Unknown 56 10.7
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Males constituted 45.6% of the population. Among patients, 30.5
and 32.3% were in a first-line setting of palliative chemotherapy
and adjuvant chemotherapy setting, respectively. Breast cancer was
the most common cancer type (168, 32.1%), and most patients
ranged in age from 40 to 70 years (410, 78.2%). In terms of the
degree of education, 71.6% of the population had gone beyond
high school. Most patients were married and lived within a 2-h
distance of the hospital (81.1 and 66.4%, respectively). The rate of
patients with private cancer insurance was 48.3% (253). The
economic status of patients was evenly distributed (Table 1).
Cancer patients’ awareness of CTs
For the question ‘Have you ever heard about cancer CTs?’, 433
(82.6%) individuals answered ‘yes’. Mass media such as TV,
internet, and newspapers was the most important source of
information (68%). The second source was a physician (22%). The
others were relatives and other patients (15 and 6%, respectively).
Younger age, higher educational degree, higher economic status,
and possession of private insurance were associated with a higher
rate of awareness for CTs (P¼0.001, P¼0.006, P¼0.002, and
P¼0.009, respectively). However, disease status and marital status
were not related to awareness of CTs (Table 2).
Perceptions of cancer patients regarding the effects of CTs
compared with conventional therapy
In the evaluation of the perceptions on effects of treatments using a
VAS, most patients marked over five points (Figure 1). Figure 1
also revealed that most patients had positive perceptions on the
effects of CTs as compared with conventional therapy (mean
VAS¼6.95±2.00 and 6.56±2.04, respectively; Po0.001, benefit¼
0.38±2.09). Both males and females had positive perceptions but
males had more positive perceptions than females (benefit¼
0.74±2.07 and 0.11±2.07, respectively; P¼0.002). In the group
of more heavily treated patients, patients favoured the treatments
offered in CTs more positively (P¼0.001). However, in terms of
neoadjuvant and adjuvant disease status, patients had negative
views of the treatments used in CTs (benefit¼ 0.12±1.71 and
 0.10±2.36, respectively). Patients without private cancer insur-
ance had more positive perceptions on the effects of CTs than
patients with private cancer insurance (benefit¼0.58±1.90 and
0.16±2.25, respectively; P¼0.043). Other variables such as age,
educational degree, economic status, and type of religion did not
influence the perceptions of patients regarding the benefits of CTs
as compared with conventional therapy (Table 3). Awareness of
CTs did not also affect the perceptions of patients regarding the
benefits of CTs (benefit¼0.40±2.12 for patients with awareness of
CTs and 0.26±1.95 for patients without awareness; P¼0.631).
Willingness of cancer patients to participate in CTs
If CTs were available and a recommendation was given from
their physician, 64.7% patients answered that they would be willing
to participate in CTs. These patients mostly believed that
Table 1 (Continued)
Variable Frequency (N¼524) %
Distance from clinic
p2h 348 66.4
42h 176 33.6
Private cancer insurance
Yes 253 48.3
No 248 47.3
Unknown 23 4.4
aThyroid cancer, thymic carcinoma, germ cell tumour, skin cancer, neuroendocrine
carcinoma, mesothelioma, anal cancer, brain, melanoma, renal cell carcinoma,
metastatic of unknown origin, and small bowel cancer.
bThousands United States
dollars per month.
Table 2 Patients’ awareness of cancer clinical trials
Variable Awareness of clinical trial (%) P-value
Sex
Male 194/239 (81.2) 0.418
a
Female 239/285 (83.9)
Age (years)
p30 11/12 (91.7) 0.001
b
30o to p40 54/59 (91.5)
40o to p50 103/121 (85.1)
50o to p60 112/128 (87.5)
60o to p70 121/161 (75.2)
70o 32/43 (74.4)
Disease status
Neoadjuvant 19/25 (76.0) 0.186
b
Adjuvant 134/169 (79.3)
Metastatic, first line 129/161 (80.1)
Metastatic, second line 72/78 (92.3)
Metastatic, third line 40/49 (81.6)
Metastatic, fourth line 19/21 (90.5)
Metastatic, fifth line 10/11 (90.9)
Metastatic, sixth line 8/8 (100.0)
Metastatic, seventh line 2/2 (100.0)
Marital status
Single 30/34 (88.2) 0.144
a
Married 354/425 (83.3)
Bereavement 20/29 (69.0)
Divorced 15/20 (75.0)
Educational degree
Postgraduate 33/37 (89.2) 0.006
b
University 131/153 (85.6)
High school 153/185 (82.7)
Middle school 49/57 (86.0)
Elementary school 40/58 (69.0)
Uneducated 7/10 (70.0)
Economic status
45
c 56/64 (87.5) 0.002
b
5X to 44 42/46 (91.3)
4X to 43 70/78 (89.7)
3X to 42 51/58 (87.9)
2X to 41 75/93 (80.6)
1X 97/129 (75.2)
Religion
Buddhism 128/167 (79.0) 0.018
a
Christian 135/153 (88.2)
Catholicism 64/74 (86.5)
Others 58/79 (73.4)
Private cancer insurance
Yes 221/253 (87.4) 0.009
a
No 195/248 (78.6)
Distance from clinic
p2h 286/348 (82.2) 0.702
a
42h 147/176 (83.5)
aPearson w
2.
bLinear-by-linear association.
cThousands United States dollars per
month.
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state-of-the-art treatments (46%). Some patients answered that
they would not decline participation just to have no other
treatment options, or that they wanted to participate because of
recommendations from their relatives (20 and 20%, respectively).
A few patients reported the reasons to be the economic benefit of
participation (14%). In contrast, the patients who answered that
they did not want to participate in CTs believed that therapies used
in CTs were not yet proven to be more effective than conventional
therapies (54%). Some patients answered that they would not want
to be experimental tools for new treatments (27%). Others were
concerned about adverse effects of the treatment used in CTs
(11%). Fear of randomisation was mentioned by 7% of individuals
(14). A few patients refused to participate because of the opinions
of family members (4%).
Males were more likely to participate in CTs than females
(P¼0.023). In adjuvant, neoadjuvant disease status, and
first-line palliation, the rates of willingness to participate in CTs
were lower than that of heavily treated metastatic cancer
patients (P¼0.003; Table 4). In multivariate analysis, male and
heavily treated patients were also more willing to participate
in cancer CTs (OR¼1.17, 1.14–2.75, P¼0.01: OR¼1.59, 1.01–
2.51, P¼0.04, respectively; Table 5). Other factors, including
economic status, educational degree, marital status, distance
from home to hospital, and possession of private cancer insurance
did not influence the willingness to participate in clinical
trials. Overall, patients’ awareness of clinical trials influenced
the willingness to participate in clinical trials (OR¼1.938, 95% CI:
1.22–3.07, P¼0.005). However, in contrast to the increased
awareness in younger patients, those with a higher educational
degree, higher economic status, and possession of private
cancer insurance, the willingness was not increased in these
conditions (P¼0.381, P¼0.775, P¼0.887, and P¼0.392,
respectively). In terms of benefits and willingness, the benefit
of participation in CTs as compared with conventional
therapy also influenced the willingness to participate in CTs
(OR¼1.31, 95% CI: 1.174–1.463, Po0.001). The more
positive perception of benefits in males and heavily treated
patients was in line with the findings of the willingness of patients
to participate in CTs.
Differences in the perception on the effects of treatment
between cancer patients and their physicians
The physicians also answered questions about how much their
patients might benefit from each therapy. Forty-five paired
answers from both patients and their physicians were collected
for perceptions on the effects of conventional therapy, and 42
paired answers were received for perceptions of CTs. For each of
the conventional therapies and treatments used in CTs, physicians
had less positive perceptions than the patients did (Po0.01 and
P¼0.028, respectively; Table 6). However, despite a lack of
significance, physicians thought that participation in CTs would be
more beneficial over conventional therapy than patients thought
(benefit¼1.14±1.60 and 0.76±2.49, respectively; P¼0.229).
DISCUSSION
To our knowledge, this study represents the first large prospective
study for perceptions of CTs in eastern countries. Considering that
the number of cancer CTs and the proportion of global trials
performed in the East are increasing rapidly, this subject should
be interesting in the East. To evaluate sound perceptions of
cancer patients at the step of actual enrolment, eligible patients
were limited only to those at the start of the first cycle of their
chemotherapy, who were usually considered to be actual
candidates for participation in CTs. The most earlier studies
regarding cancer patients’ perceptions of CTs were reported in
particular cancer types, patients in phase I trials, or the general
population (Weeks et al, 1998; Comis et al, 2003; Meropol et al,
2003; Agrawal et al, 2006). Patients’ perceptions could easily be
changed according to patient conditions when faced with the
recommendation to participate in CT (Gotay, 1991; Ross et al,
1999; Ellis, 2000). Therefore, it is valuable to confine this study to
patients who could actually be considered as candidates of CTs at
the point of enrolment. In addition, the perceptions regarding the
effects of CTs and conventional therapy were quantified using
VAS. Then, the benefit of participation in CTs was calculated
through VAS scores. This quantitative approach was unique and
decisive to define the difference of perceptions in various
conditions.
Patients
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Figure 1 Visual analogue scale (VAS) on effects of clinical trial (CT) and conventional therapy. (A) Distribution. The size of solid circle indicates the
number of patients. (B) The benefit of participation in clinical trials. A positive value indicates a higher expectation of benefits for the clinical trial therapy.
Zero points indicate equal expectation of both therapies.
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this study, the mass media strongly influenced the awareness of
CTs. Therefore, campaigning through mass media could be a good
tool to increase the awareness of CTs. In fact, efforts have been
made to increase the awareness of cancer CTs through internet
websites in the United States. The 22% of sources from physicians
Table 3 Benefits of the effect of clinical trial therapy as compared with
conventional treatment
Variable (N) Benefit (mean±s.d.) P-value
Sex
Male (184) 0.74±2.07 0.002
a
Female (244) 0.11±2.07
Age (years)
p30 (11) 1.18±1.47 0.709
b
30o to p40 (51) 0.41±2.09
40o to p50 (108) 0.19±2.15
50o to p60 (106) 0.31±2.32
60o to p70 (118) 0.43±1.78
70o to (34) 0.73±2.28
Line
Neoadjuvant (20)  0.12±1.71 0.001
b
Adjuvant (151)  0.10±2.36
Metastatic, first line (121) 0.47±1.62
Metastatic, second line (58) 0.58±1.77
Metastatic, third line (38) 0.77±2.21
Metastatic, fourth line (20) 1.25±1.65
Metastatic, fifth line (10) 1.70±2.35
Metastatic, sixth line (8) 2.00±3.33
Metastatic, seventh line (2) 2.00±2.82
Marital status
Single (28) 1.14±1.26 0.028
b
Married (353) 0.38±2.11
Bereavement (23)  0.47±2.23
Divorced (15) 1.00±1.13
Educational degree
Postgraduate (34) 0.32±1.42 0.92
b
University (135) 0.32±2.24
High school (152) 0.53±1.96
Middle school (44) 0.31±2.34
Elementary school (41) 0.31±1.91
Uneducated (7)  0.14±2.54
Economic status
45
c (55) 0.36±1.97 0.847
b
5X to 44 (40) 0.07±2.11
4X to 43 (68) 0.33±2.46
3X to 42 (51) 0.52±1.75
2X to 41 (79) 0.60±1.73
1X (104) 0.41±2.25
Religion
Buddhism (130) 0.37±2.29 0.717
b
Christian (129) 0.22±2.03
Catholicism (64) 0.59±2.02
Others (65) 0.40±2.04
Private cancer insurance
Yes (207) 0.16±2.25 0.043
a
No (203) 0.58±1.90
Distance from Clinic
p2h (288) 0.49±1.87 0.129
a
42h (140) 0.16±2.46
Awareness of clinical trial
Yes (366) 0.40±2.12 0.631
a
No (62) 0.26±1.95
at-test.
bOne-way analysis of variances.
cThousands United States dollars per month.
Table 4 Willingness of patients to participate in cancer clinical trials
Variable Willingness for clinical trial (%) P-value
Sex
Male 163/233 (70.0) 0.023
a
Female 167/277(60.3)
Age (years)
p30 8/12 (66.7) 0.381
b
30o to p40 36/59 (61.0)
40o to p50 68/114 (59.6)
50o to p60 87/125 (69.6)
60o to p70 103/157 (65.6)
o70 28/43 (65.1)
Line
Neoadjuvant 14/25 (56.0) 0.003
b
Adjuvant 93/167 (55.7)
Metastatic, first line 105/156 (67.3)
Metastatic, second line 54/76 (71.1)
Metastatic, third line 35/46 (76.1)
Metastatic, fourth line 14/20 (70.0)
Metastatic, fifth line 8/10 (80.0)
Metastatic, sixth line 6/8 (75.0)
Metastatic, seventh line 1/2 (50.0)
Marital status
Single 22/34 (64.7) 0.886
a
Married 268/415 (64.6)
Bereavement 20/29 (69.0)
Divorced 13/18 (72.2)
Educational degree
Postgraduate 24/36 (66.7) 0.775
b
University 95/152 (62.5)
High school 119/179 (66.5)
Middle school 35/53 (66.0)
Elementary school 35/57 (61.4)
Uneducated 8/10 (80.0)
Economic status
45
c 38/61 (62.3) 0.887
b
5X to 44 31/46 (67.4)
4X to 43 50/75 (66.7)
3X to 42 39/58 (67.2)
2X to 41 56/90 (62.2)
1X 83/125 (66.4)
Religion
Buddhism 94/159 (59.1) 0.205
a
Christian 92/146 (63.0)
Catholicism 53/73 (72.6)
Others 53/78 (67.9)
Private cancer insurance
Yes 152/243 (62.6) 0.392
a
No 163/246 (66.3)
Distance from clinic
p2h 226/337 (67.1) 0.120
a
42h 104/173 (60.1)
Awareness of clinical trial
Yes 284/421 (67.5) 0.004
a
No 46/89 (51.7)
aPearson w
2.
bLinear-by-linear association.
cThousands United States dollars per
month.
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smight indirectly reflect the proportion of physicians’ recommen-
dations for their patients to participate in CTs. It was recently
reported that physicians were the main resource of patients’
awareness and, in addition, strongly influenced participation in
cancer CTs (Comis et al, 2006).
Overall, willingness appeared to significantly reflect the aware-
ness and perceptions on the benefit of CTs in this study. These
results were in concordance with the relationship between
awareness and willingness shown in earlier reports (Comis et al,
2003; Lara et al, 2005). However, awareness did not reflect
perceptions on the benefit. From this finding, it could be inferred
that patients’ awareness does not necessarily indicate positive
perceptions of CTs.
Participation in cancer CTs has increased overall since the early
1990s, but this has not been the case in cancer populations in low
socioeconomic groups, the elderly, and ethnic minorities (Kaluzny
et al, 1993; Trimble et al, 1994; Tejeda et al, 1996; Sateren et al,
2002; Christian and Trimble, 2003; Murthy et al, 2004). However,
in this study, the rate of willingness to participate in CTs and the
positive perceptions on the benefits of participation were not lower
in the elderly or in patients with a lower socioeconomic status
group, despite the fact that they had lower rates of awareness of
CTs. Therefore, a lower accrual rate for CTs might originate from
fewer opportunities to participate in CTs offered by investigators
in the elderly or in the poor socioeconomic group, rather than the
reluctance of patients to participate in CTs.
Heavily treated patients had more optimistic views of CTs and
were more willing to participate in CTs compared with less heavily
treated patients. These findings are supportive of an earlier study,
in which patients facing life-threatening illnesses would weigh
potential benefits and discount the risks associated with treatment
(Gaskin et al, 1998). From these results, it could be expected that,
in CTs with heavily treated cancer patients, it was not relatively
difficult to enrol patients. In addition, because of negative views of
cancer CTs in adjuvant, neoadjuvant, or early treatment steps,
more comprehensive explanation of the benefits and aims of CT
has to be given to candidates before they were willing to be
enrolled in CT.
Insurance and funding also influenced the accrual of patients in
cancer CTs (Lara et al, 2001, 2005). Possession of private cancer
insurance cannot only reflect the concern for economic problems,
but may also reflect health care issues. Therefore, it was explained
that patients with private cancer insurance had greater awareness
of CTs in this study. However, this higher awareness in patients
with private cancer insurance was not linked with willingness to
participate in CTs. These patients with private cancer insurance
might be most likely to doubt the benefits of CTs, even though CTs
tended to offer lots of benefits.
Another study mentioned the distance from the clinic as one of
the reasons for accrual barriers (Lara et al, 2001). Although this
was not significant, this tendency was shown in this study.
Therefore, effective measures to offer a chance for patients far
from a clinic to participate in CTs should be sought.
In terms of reasons of participation in CT, some agreed to
participate because of recommendation by relatives (20%). A few
patients refused to participate because of the opinions of family
members (4%). These might reflect the culture in Korea, that is,
lower patient autonomy in the treatment decision-making process.
Most patients who did not want to participate in CTs were
concerned about the efficacy and effectiveness of CTs. However,
the aim of CT is usually the verification of the efficacy of a new
treatment modality based on preclinical study and logical rationale
that the CT therapy could be superior to or at least not inferior
to conventional therapy. Therefore, these perceptions of cancer
patients could be changed with comprehensive explanations
of CTs.
In concordance with another earlier reports (Weeks et al, 1998;
Meropol et al, 2003), patients had a more optimistic view for the
effect of each of the treatments than physicians expected. These
results indicate the possibility of potential communication barriers
between patients and physicians. However, physician thought that
participation in cancer CTs was more beneficial as compared with
patients thought. Physicians should carefully consider the
expectancy of patients in CTs to manage the compliance of
patients in CTs.
The limitation of this study is that the level of awareness was not
evaluated. In an earlier report, the level of knowledge was
significantly associated with willingness to participate in CTs
(Lara et al, 2005). It could be completely expected that the quality
and quantity of awareness directly influenced the willingness of
patients to participate in CTs from this study. Another limitation is
selection bias. Our data did not include all the patients of
candidates for study period and only 62% patients of all the
candidates in this study responded to the questionnaire. This low
response rates might be resulted from the perplexed condition at
that time of request for questionnaire because patients were
noticed that their disease progressed or that new cancer diagnosed.
In these bewildered situations, patients were uncooperative to
Table 5 Multivariate analysis for willingness
Variable P-value Odds ratio 95% CI
Male 0.01 1.17 1.14–2.75
Old age (X60) 0.36 0.80 0.50–1.28
Heavily treated
a 0.04 1.59 1.01–2.51
High educational degree (Xuniversity) 0.25 0.77 0.49–1.20
High economic status (X3 thousands United States dollars per month) 0.49 1.16 0.75–1.81
Private cancer insurance 0.60 0.89 0.58–1.37
42h, distance from clinic 0.06 0.67 0.44–1.02
aX second-line palliative therapy (vs adjuvant, neoadjuvant, and first-line palliative chemotherapy).
Table 6 Different view between patients and physicians regarding effect of treatment
Variable (N) Patients (mean±s.d.) Physicians (mean±s.d.) P-value
Conventional therapy (45) 6.37±2.04 5.08±2.02 o0.01
a
Cancer clinical therapy (42) 7.14±1.84 6.28±1.83 0.028
a
Benefit (42) 0.76±2.49 1.14±1.60 0.229
a
aPaired t-test.
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srespond to questionnaire. This study has been conducted in one
hospital of Korea. Therefore, it could not be easy that the data of
this study include all eastern perceptions of CT. Nevertheless, these
data could give evidence that is representative of the perceptions in
eastern countries.
This study addresses that perceptions of cancer patients such as
awareness, perception on the benefit of CTs, and willingness to
participate in CTs are influenced by socioeconomic background,
disease status, age, and sex. These results would be conducive to
physicians’ understanding proper patients’ perceptions of CTs in
pertinent conduct of cancer CTs in the East.
ACKNOWLEDGEMENTS
We thank clinical research nurses (Seoul National University
Hospital) to help this study and patients to participate in this
study.
REFERENCES
Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ
(2006) Patients’ decision-making process regarding participation in
phase I oncology research. J Clin Oncol 24: 4479–4484
Christian MC, Trimble EL (2003) Increasing participation of physicians and
patients from underrepresented racial and ethnic groups in National
Cancer Institute-sponsored clinical trials. Cancer Epidemiol Biomarkers
Prev 12: 277s–283s
Cobau CD (1994) Clinical trials in the community. The community clinical
oncology program experience. Cancer 74: 2694–2700
Comis RL, Colaizzi D, Miller JD (2006) Cancer clinical trials (CCT)
awareness and attitudes in cancer survivors (Ca surv). J Clin Oncol
(Meeting Abstracts) 24: 6061
Comis RL, Miller JD, Aldige CR, Krebs L, Stoval E (2003) Public attitudes
toward participation in cancer clinical trials. J Clin Oncol 21: 830–835
Dilts DM, Sandler AB (2006) Invisible barriers to clinical trials: the impact
of structural, infrastructural, and procedural barriers to opening
oncology clinical trials. J Clin Oncol 24: 4545–4552
Ellis PM (2000) Attitudes towards and participation in randomised clinical
trials in oncology: a review of the literature. Ann Oncol 11: 939–945
Gaskin DJ, Kong J, Meropol NJ, Yabroff KR, Weaver C, Schulman KA
(1998) Treatment choices by seriously ill patients: the Health Stock Risk
Adjustment model. Med Decis Making 18: 84–94
Gotay CC (1991) Accrual to cancer clinical trials: directions from the
research literature. Soc Sci Med 33: 569–577
Haidich AB, Ioannidis JP (2001) Effect of early patient enrollment on the
time to completion and publication of randomized controlled trials. Am J
Epidemiol 154: 873–880
Ho J, Pond G, Newman C, Maclean M, Chen E, Oza A, Siu L (2006) Barriers
in phase I cancer clinical trials referrals and enrollment: five-year
experience at the Princess Margaret Hospital. BMC Cancer 6: 263
Kaas R, Hart AAM, Rutgers EJT (2005) The impact of the physician on the
accrual to randomized clinical trials in patients with primary operable
breast cancer. The Breast 14: 310–316
Kaluzny A, Brawley O, Garson-Angert D, Shaw J, Godley P, Warnecke R,
Ford L (1993) Assuring access to state-of-the-art care for U.S. minority
populations: the first 2 years of the Minority-Based Community Clinical
Oncology Program. J Natl Cancer Inst 85: 1945–1950
Lara Jr PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T,
Welborn J, Meyers FJ, Christensen S, O’Donnell R, Richman C, Scudder
SA, Tuscano J, Gandara DR, Lam KS (2001) Prospective evaluation of
cancer clinical trial accrual patterns: identifying potential barriers to
enrollment. J Clin Oncol 19: 1728–1733
Lara Jr PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell
L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T,
Beckett LA, Chen Jr MS (2005) Evaluation of factors affecting awareness
of and willingness to participate in cancer clinical trials. J Clin Oncol 23:
9282–9289
Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson III AB, Castel L,
Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland
JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA
(2003) Perceptions of patients and physicians regarding phase I cancer
clinical trials: implications for physician-patient communication. J Clin
Oncol 21: 2589–2596
Murthy VH, Krumholz HM, Gross CP (2004) Participation in
cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291:
2720–2726
Paterniti DA, Chen Jr MS, Chiechi C, Beckett LA, Horan N, Turrell C, Smith
L, Morain C, Montell L, Luis Gonzalez J, Davis S, Lara Jr PN (2005) Asian
Americans and cancer clinical trials: a mixed-methods approach to
understanding awareness and experience. Cancer 104: 3015–3024
Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R (1999)
Barriers to participation in randomised controlled trials: a systematic
review. J Clin Epidemiol 52: 1143–1156
Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L,
McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC (2002)
How sociodemographics, presence of oncology specialists, and hospital
cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:
2109–2117
Stiller CA (1994) Centralised treatment, entry to trials and survival. Br J
Cancer 70: 352–362
Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS,
Friedman MA, Brawley OW (1996) Representation of African-Americans,
Hispanics, and whites in National Cancer Institute cancer treatment
trials. J Natl Cancer Inst 88: 812–816
Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA
(1994) Representation of older patients in cancer treatment trials. Cancer
74: 2208–2214
Tu SP, Chen H, Chen A, Lim J, May S, Drescher C (2005) Clinical trials:
understanding and perceptions of female Chinese-American cancer
patients. Cancer 104: 2999–3005
Weeks JC, Cook EF, O’Day SJ, Peterson LM, Wenger N, Reding D, Harrell
FE, Kussin P, Dawson NV, Connors Jr AF, Lynn J, Phillips RS (1998)
Relationship between cancer patients’ predictions of prognosis and their
treatment preferences. Jama 279: 1709–1714
Eastern perceptions of cancer clinical trial
JW Kim et al
1599
British Journal of Cancer (2008) 99(10), 1593–1599 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s